Justin Frazier is Vice President of Clinical Affairs at DermaSensor, where he has led the company’s clinical function since 2017. He is responsible for clinical strategy and execution across DermaSensor’s global study portfolio, including pre-market development, post-market surveillance, real-world evidence generation, and clinical programs supporting regulatory, reimbursement, and commercial objectives for AI-enabled diagnostic technologies. In this role, he helped lead the clinical programs that supported DermaSensor’s FDA clearance in 2024.
With more than 17 years of experience in medical device clinical development, Justin has built and scaled clinical programs across start-up and large MedTech environments. His background includes leadership roles at ReWalk Robotics, Smith & Nephew, Covidien/Medtronic, Massachusetts General Hospital, and PAREXEL, with deep experience overseeing complex, multi-site studies, managing CROs and vendors, and partnering closely with regulatory, medical, and executive teams.
Justin holds a Master of Science in Regulatory and Clinical Research Management and is known for bringing operational rigor, regulatory discipline, and pragmatic execution to clinical programs supporting innovative medical technologies.